

PRARAM 9 HOSPITAL PR9 TB

THAILAND / HEALTH CARE SERVICES

BUY

UNCHANGED

Scope for further foreign growth

- คาดกลุ่มคนไข้ชาวต่างชาติ หนุนรายได้ปี 2026 เติบโต 8% ขณะที่การรักษาโรคซับซ้อนเพิ่มขึ้น และการควบคุมต้นทุน จะเพิ่ม EBITDA margin เป็น 24.6%
- ประมาณการกำไรปกติปี 2026 ขยายตัว 10% คาดกำไร 1Q26 ลดลง 3% q-q แต่ยังคงเติบโต 5% y-y
- คงคำแนะนำ ซื้อ และเป็นหุ้น Top Pick กลุ่มการแพทย์ บน valuation ไม่แพงที่ 18x P/E ปี 2026 (-1.0 SD)

TARGET PRICE	THB29.25
CLOSE	THB20.50
UP/DOWNSIDE	+42.7%
PRIOR TP	THB30.00
CHANGE IN TP	-2.5%
TP vs CONSENSUS	+13.5%

KEY STOCK DATA

YE Dec (THB m)	2025	2026E	2027E	2028E
Revenue	5,277	5,703	6,110	6,545
Net profit	823	905	1,010	1,120
EPS (THB)	1.05	1.15	1.28	1.42
vs Consensus (%)	-	10.6	12.2	14.4
EBITDA	1,276	1,421	1,580	1,723
Recurring net profit	823	905	1,010	1,120
Core EPS (THB)	1.05	1.15	1.28	1.42
Chg. In EPS est. (%)	-	(2.1)	(1.3)	(1.2)
EPS growth (%)	15.4	10.0	11.6	10.8
Core P/E (x)	19.6	17.8	16.0	14.4
Dividend yield (%)	2.4	2.8	3.1	3.5
EV/EBITDA (x)	10.5	9.4	8.1	7.0
Price/book (x)	2.7	2.5	2.3	2.1
Net debt/Equity (%)	(45.4)	(42.8)	(48.3)	(53.3)
ROE (%)	14.5	14.8	15.2	15.4

กลุ่มคนไข้ชาวต่างชาติยังคงขับเคลื่อนการเติบโตในปี 2026

เราคาดว่ากำไรปกติของ PR9 ในปี 2026 จะขับเคลื่อนโดยกลุ่มคนไข้ชาวต่างชาติ ได้รับแรงหนุนจากอุปสงค์ที่แข็งแกร่งจากตะวันออกกลาง (กาตาร์ยังเติบโตดี และมี upside จากโมเมนต์ที่ดีขึ้นในโอมาน UAE และคูเวต) รวมถึงอาเซียน และการรุกตลาดใหม่ๆ ซึ่งกลุ่มคนไข้จากตะวันออกกลางยังมีโอกาสเติบโตอีกมากจากฐานรายได้ที่ยังเล็ก ขณะที่การเติบโตของกลุ่มคนไข้ชาวไทยคาดว่าจะจำกัดจากภาวะเศรษฐกิจในประเทศ บริษัทตั้งเป้ารายได้เติบโต 6-8% y-y เป็นกรณีฐาน (base case) ขณะที่ประมาณการของเราเติบโต 8% เป็นกรอบบนของเป้าหมาย เราคาดว่ารายได้จากคนไข้ชาวต่างชาติจะเพิ่มขึ้น 26% y-y หนุนสัดส่วนรายได้เพิ่มเป็น 30% (2025: 26%) ส่วนรายได้จากคนไข้ชาวไทยคาดว่าจะเพิ่มขึ้น 2% y-y

การลงทุนและการควบคุมต้นทุนจะหนุนมาร์จิ้น


PR9 วางงบลงทุนปี 2026 ที่ 700 ลบ. โดย 70% ใช้ลงทุนจัดซื้อเครื่องมือแพทย์ขั้นสูง เพื่อยกระดับการรักษา (เช่น หุ่นยนต์ผ่าตัด ใน 1Q26) และระบบบริหารจัดการโรงพยาบาลใน 2Q26 การลงทุนดังกล่าวจะช่วยเพิ่มสัดส่วนการรักษารักษาโรคซับซ้อน และเพิ่มประสิทธิภาพการดำเนินงาน หนุนการขยายตัวของมาร์จิ้น ขณะเดียวกัน ยังตั้งเป้าควบคุมค่าใช้จ่ายการตลาด โดยเน้นไปยังกลุ่มตลาดใหม่ และต่อยอดจากการสร้างแบรนด์ในปีก่อน ส่วนต้นทุนที่ประหยัดได้จากการลงระบบใหม่ จะชดเชยค่าเสื่อมราคาที่สูงขึ้น เราคาดว่า EBITDA margin ปี 2026 จะเพิ่มขึ้นอีก 0.7ppt เป็น 24.6% บน revenue intensity และการควบคุมต้นทุน โดยยังคงจุดยืนด้านความคุ้มค่าของการรักษาโดยไม่ปรับขึ้นราคา

คาดการณ์กำไร 1Q26 ยังเติบโต y-y

เราปรับปรุงสมมติฐานค่าเสื่อมราคาและ SG&A เล็กน้อย โดยปรับลดประมาณการกำไรปี 2026-2028 ลง 1-2% ซึ่งคาดว่าจะกำไรปกติยังเติบโตแข็งแกร่ง 10% ในปี 2026 และ 11-12% ในปี 2027-2028 เราคาดการณ์เบื้องต้นว่า 1Q26 จะมีกำไรปกติ 212 ลบ. ลดลง 3% q-q ตามฤดูกาล แต่ยังคงเติบโต 5% y-y จากรายได้คนไข้ต่างชาติขยายตัวต่อเนื่อง และผลกระทบช่วงเดือนรอมฎอนจำกัด จากนัดหมายแพทย์ล่วงหน้า ขณะที่รายได้คนไข้ชาวไทยเติบโตเพียงเล็กน้อย คาดมาร์จิ้นยังมีแรงหนุนจากส่วนผสมเคสซับซ้อน และการคุมค่าใช้จ่ายดำเนินงาน

คงคำแนะนำ ซื้อ จากแนวโน้มกำไรเติบโตแข็งแกร่งและมีความชัดเจน

เราปรับลดราคาเป้าหมาย (DCF) เล็กน้อย เป็น 29.25 บาท (จาก 30 บาท) ราคาหุ้นปัจจุบันซื้อขายที่ 18x P/E ปี 2026 (-1.0 SD เทียบค่าเฉลี่ย 5 ปี) ซึ่งยังไม่แพง เรายังคงให้ PR9 เป็นหุ้นเด่นกลุ่มการแพทย์ จากแนวโน้มกำไรที่คาดว่าจะมีความชัดเจนต่อการเติบโตแบบ double-digit นำโดยกลุ่มคนไข้ชาวต่างชาติ ขณะที่ประเด็นการตั้งสำรองลูกหนี้ได้คลี่คลาย และคาดการณ์ผลตอบแทนเงินปันผลราว 3% ต่อปี



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	6.8	4.6	(11.6)
Relative to country (%)	(6.5)	(9.4)	(25.6)
Mkt cap (USD m)	517		
3m avg. daily turnover (USD m)	1.4		
Free float (%)	59		
Major shareholder	Khunying Potjaman Damapong (37%)		
12m high/low (THB)	26.75/16.70		
Issued shares (m)	786.30		

Sources: Bloomberg consensus; FSSIA estimates



Vatcharut Vacharawongsith

Fundamental Investment Analyst on Securities; License no. 018301
vacharut.v@fssia.com, +66 2646 9969

Investment thesis

PR9’s foreign patient revenue remains the primary growth driver. It is expected to increase 26% in 2025 and maintain strong double-digit growth through 2028. Increased bed capacity by 10% in 2026 and ongoing expansion in Middle Eastern source markets will further support revenue and margin upside.

Stable performance from the Thai patient segment complements growth, with a targeted revenue mix at 65-70%. Despite short-term seasonal and economic challenges, we forecast Thai patient revenue to grow steadily at 3% p.a. through 2028.

We expect core profit growth of 11% CAGR and revenue growth of 7% CAGR over 2026-2028. Our estimated increase in revenue mix from international patients from 26% in 2025 to 35% in 2028 supports strong topline momentum and operational efficiencies. This should improve the EBITDA margin and ROE, potentially leading to a stock valuation re-rating, in our view.


Company profile

PR9 has been operating a private hospital since 1992.

www.praram9.com

Principal activities (revenue, 2025)


- OPD patient revenue - 54.2 %
- IPD patient revenue - 45.8 %



Source: Praram 9 Hospital

Major shareholders

- Khunying Potjaman Damapong - 37.3 %
- Thai NVDR - 3.9 %
- Vayupak Fund 1 - 1.9 %
- Others - 57.0 %



Source: Praram 9 Hospital

Catalysts

Key potential growth drivers include 1) a higher Thai patient volume from new specialist centers; 2) rising demand from medical tourists, especially patients from CLMV, China, and the Middle East; and 3) the strategy to capture Middle East patients.

Risks to our call

Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Event calendar

Date	Event
May 2026	1Q26 results announcement

Key assumptions

	2026E (%)	2027E (%)	2027E (%)
No of license beds (no.)	224	249	249
OPD Volume growth	3	3	3
OPD revenue / patient growth	5	4	4
IPD Volume growth	3	3	3
IPD revenue / patient growth	5	4	4


Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2026 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2026 earnings to rise by 5%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: Revenue contribution from international patients




Sources: PR9; FSSIA estimates

Exhibit 2: International patient revenue




Sources: PR9; FSSIA estimates

Exhibit 3: Thai patient revenue




Sources: PR9; FSSIA estimates

Exhibit 4: PR9's revenue breakdown by payor




Sources: PR9; FSSIA's compilation

Exhibit 5: Total patient revenue




Sources: PR9; FSSIA estimates

Exhibit 6: Core profit




Sources: PR9; FSSIA estimates

Exhibit 7: Profit margins



Sources: PR9; FSSIA estimates

Exhibit 8: ROE



Sources: PR9; FSSIA estimates

Exhibit 9: Earnings forecast revisions

	Current			Previous			Change		
	2026E (THB m)	2027E (THB m)	2028E (THB m)	2026E (THB m)	2027E (THB m)	2028E (THB m)	2026E (%)	2027E (%)	2028E (%)
Revenue	5,703	6,110	6,545	5,703	6,110	6,545	0.0	0.0	0.0
Gross profit margin (%)	37.2	37.4	37.8	37.2	37.5	37.9	(0.0)	(0.2)	(0.2)
SG&A/sales ratio (%)	19.4	18.7	18.5	19.0	18.7	18.5	0.4	0.0	0.0
EBITDA margin (%)	24.6	25.6	26.0	25.0	25.6	26.1	(0.4)	(0.0)	(0.0)
Core profit	905	1,010	1,120	924	1,024	1,134	(2.1)	(1.3)	(1.2)
Key assumptions									
OPD- Visiting numbers per day (no.)	1,651	1,700	1,751	1,651	1,700	1,751	0.0	0.0	0.0
OPD - Revenue per visit (THB)	5,150	5,356	5,570	5,150	5,356	5,570	0.0	0.0	0.0
IPD - Admission numbers per day (no.)	48	50	51	48	50	51	0.0	0.0	0.0
IPD- Revenue per admission (THB)	147,152	153,038	159,160	147,152	153,038	159,160	0.0	0.0	0.0


Source: FSSIA estimates

Exhibit 10: DCF valuation

Cost of equity assumptions		(%)	Cost of debt assumptions		(%)
Risk-free rate		3.0	Pre-tax cost of debt		3.5
Market risk premium		8.5	Marginal tax rate		20.0
Stock beta		0.8			
Cost of equity, Ke		9.5	Net cost of debt, Kd		2.8
Weight applied		100.0	Weight applied		0.0
WACC		9.5			
DCF valuation estimate (THB m)					
NPV		7,990			
Terminal value		12,054			
Cash & liquid assets		2,739			
Investments		104			
Debt		(5)			
Minorities		0			
Residual ordinary equity		22,883			
No. of shares (m)		786			
Equity value per share (THB)		29.25			


Source: FSSIA estimates

Exhibit 11: Prospective P/E band



Sources: Bloomberg consensus; FSSIA estimates

Exhibit 12: Prospective EV/EBITDA band



Source: Bloomberg consensus; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Revenue	4,635	5,277	5,703	6,110	6,545
Cost of goods sold	(3,045)	(3,346)	(3,585)	(3,827)	(4,073)
Gross profit	1,590	1,930	2,119	2,282	2,471
Other operating income	55	65	66	68	70
Operating costs	(837)	(1,032)	(1,109)	(1,145)	(1,214)
Operating EBITDA	1,114	1,276	1,421	1,580	1,723
Depreciation	(306)	(313)	(346)	(376)	(396)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	808	963	1,075	1,204	1,327
Net financing costs	54	51	56	58	73
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	862	1,013	1,131	1,263	1,400
Tax	(149)	(191)	(226)	(253)	(280)
Profit after tax	713	823	905	1,010	1,120
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	713	823	905	1,010	1,120
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	713	823	905	1,010	1,120
Per share (THB)					
Recurring EPS *	0.91	1.05	1.15	1.28	1.42
Reported EPS	0.91	1.05	1.15	1.28	1.42
DPS	0.40	0.50	0.58	0.64	0.71
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	10.3	13.8	8.1	7.1	7.1
Operating EBITDA (%)	16.3	14.5	11.4	11.2	9.0
Operating EBIT (%)	22.6	19.2	11.7	12.0	10.2
Recurring EPS (%)	27.8	15.4	10.0	11.6	10.8
Reported EPS (%)	27.8	15.4	10.0	11.6	10.8
Operating performance					
Gross margin inc. depreciation (%)	34.3	36.6	37.2	37.4	37.8
Gross margin exc. depreciation (%)	40.9	42.5	43.2	43.5	43.8
Operating EBITDA margin (%)	24.0	24.2	24.9	25.9	26.3
Operating EBIT margin (%)	17.4	18.2	18.9	19.7	20.3
Net margin (%)	15.4	15.6	15.9	16.5	17.1
Effective tax rate (%)	17.3	18.8	20.0	20.0	20.0
Dividend payout on recurring profit (%)	44.1	47.8	50.0	50.0	50.0
Interest cover (X)	(14.9)	(19.0)	(19.3)	(20.7)	(18.3)
Inventory days	7.0	7.3	7.5	7.3	7.3
Debtor days	24.9	32.4	40.2	41.5	42.5
Creditor days	77.9	82.8	84.2	87.5	91.1
Operating ROIC (%)	22.2	25.1	24.7	26.4	29.6
ROIC (%)	19.7	22.7	23.5	25.2	28.2
ROE (%)	13.6	14.5	14.8	15.2	15.4
ROA (%)	10.9	11.6	11.9	12.3	12.5
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
OPD patient revenue	2,731	2,862	3,103	3,324	3,561
IPD patient revenue	1,904	2,415	2,600	2,785	2,984

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Recurring net profit	713	823	905	1,010	1,120
Depreciation	306	313	346	376	396
Associates & minorities	-	-	-	-	-
Other non-cash items	(6)	12	(47)	0	0
Change in working capital	63	(146)	(42)	58	(3)
Cash flow from operations	1,076	1,002	1,161	1,444	1,512
Capex - maintenance	(251)	(500)	(700)	(371)	(331)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(128)	277	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(379)	(223)	(700)	(371)	(331)
Dividends paid	(351)	(351)	(393)	(452)	(505)
Equity finance	0	0	0	0	0
Debt finance	(4)	11	(11)	0	0
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(355)	(340)	(404)	(452)	(505)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	341	439	57	621	676
Free cash flow to firm (FCFF)	697.32	780.48	461.87	1,073.84	1,182.13
Free cash flow to equity (FCFE)	692.74	790.90	449.99	1,073.14	1,181.43

Per share (THB)	2024	2025	2026E	2027E	2028E
FCFF per share	0.89	0.99	0.59	1.37	1.50
FCFE per share	0.88	1.01	0.57	1.36	1.50
Recurring cash flow per share	1.29	1.46	1.53	1.76	1.93

Balance Sheet (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Tangible fixed assets (gross)	5,992	6,430	7,130	7,500	7,831
Less: Accumulated depreciation	(2,705)	(2,955)	(3,301)	(3,677)	(4,072)
Tangible fixed assets (net)	3,288	3,475	3,829	3,824	3,759
Intangible fixed assets (net)	0	0	0	0	0
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	382	104	104	104	104
Cash & equivalents	2,243	2,682	2,739	3,360	4,036
A/C receivable	343	595	660	729	795
Inventories	57	65	67	72	76
Other current assets	15	20	18	20	21
Current assets	2,658	3,363	3,485	4,181	4,929
Other assets	72	86	72	72	72
Total assets	6,399	7,027	7,490	8,181	8,864
Common equity	5,439	5,876	6,387	6,945	7,559
Minorities etc.	0	0	0	0	0
Total shareholders' equity	5,439	5,876	6,387	6,945	7,559
Long term debt	5	16	5	5	5
Other long-term liabilities	202	262	202	202	202
Long-term liabilities	207	278	207	207	207
A/C payable	647	729	765	889	947
Short term debt	0	0	0	0	0
Other current liabilities	106	145	131	140	150
Current liabilities	754	873	896	1,029	1,097
Total liabilities and shareholders' equity	6,399	7,027	7,490	8,181	8,864
Net working capital	(339)	(193)	(151)	(208)	(205)
Invested capital	3,402	3,472	3,855	3,792	3,730

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)	2024	2025	2026E	2027E	2028E
Book value per share	6.92	7.47	8.12	8.83	9.61
Tangible book value per share	6.92	7.47	8.12	8.83	9.61

Financial strength	2024	2025	2026E	2027E	2028E
Net debt/equity (%)	(41.2)	(45.4)	(42.8)	(48.3)	(53.3)
Net debt/total assets (%)	(35.0)	(37.9)	(36.5)	(41.0)	(45.5)
Current ratio (x)	3.5	3.9	3.9	4.1	4.5
CF interest cover (x)	(11.8)	(14.6)	(7.1)	(17.4)	(15.3)

Valuation	2024	2025	2026E	2027E	2028E
Recurring P/E (x) *	22.6	19.6	17.8	16.0	14.4
Recurring P/E @ target price (x) *	32.3	28.0	25.4	22.8	20.5
Reported P/E (x)	22.6	19.6	17.8	16.0	14.4
Dividend yield (%)	2.0	2.4	2.8	3.1	3.5
Price/book (x)	3.0	2.7	2.5	2.3	2.1
Price/tangible book (x)	3.0	2.7	2.5	2.3	2.1
EV/EBITDA (x) **	12.5	10.5	9.4	8.1	7.0
EV/EBITDA @ target price (x) **	18.6	15.9	14.3	12.4	11.0
EV/invested capital (x)	4.1	3.9	3.5	3.4	3.2

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Praram 9 Hospital; FSSIA estimates

Praram 9 Hospital PCL (PR9 TB)

FSSIA ESG rating

51.30 /100
Exhibit 13: FSSIA ESG score implication

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 14: ESG – peer comparison

	FSSIA ESG score	Domestic ratings						Global ratings					Bloomberg		
		DJSI	SET ESG	SET ESG Rating	SET ESG CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	57.16	--	Y	AA	5.00	5.00	Certified	Medium	57.79	BBB	--	60.38	35.00	--	--
BDMS	76.79	Y	Y	AAA	5.00	4.00	--	Medium	65.98	AA	34.00	53.88	86.00	4.23	63.27
BH	61.39	--	Y	A	4.00	5.00	--	Medium	63.09	A	29.00	60.66	39.00	5.83	63.35
CHG	48.96	--	Y	A	--	4.00	Declared	Medium	52.86	BBB	--	71.65	36.00	--	--
PR9	51.30	--	Y	AAA	5.00	5.00	Certified	Medium	--	--	--	65.88	--	4.54	54.07

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 15: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
ESG financial materiality scores - ESG score	—	2.33	3.01	4.07	4.54
BESG environmental pillar score	—	2.56	4.94	3.90	3.89
BESG social pillar score	—	1.36	1.56	3.80	4.69
BESG governance pillar score	—	4.13	4.66	4.67	4.75
ESG disclosure score	—	37.90	49.79	53.20	54.07
Environmental disclosure score	—	11.78	32.47	36.82	36.82
Social disclosure score	—	20.68	35.70	41.60	44.20
Governance disclosure score	—	81.10	81.10	81.10	81.10
Environmental					
Emissions reduction initiatives	No	Yes	Yes	Yes	Yes
Climate change policy	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No	No	No	Yes	Yes
Risks of climate change discussed	No	No	No	Yes	Yes
GHG scope 1	—	0	0	0	0
GHG scope 2 location-based	—	4	6	6	6
GHG Scope 3	—	0	5	5	5
Carbon per unit of production	—	—	—	—	—
Biodiversity policy	No	No	No	No	No
Energy efficiency policy	No	Yes	Yes	Yes	Yes
Total energy consumption	—	7	214	242	242
Renewable energy use	—	—	—	12	13
Electricity used	—	—	11	12	13
Fuel used - natural gas	—	—	—	—	—

Sources: Bloomberg; FSSIA's compilation

Exhibit 16: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Fuel used - crude oil/diesel	No	No	No	No	No
Waste reduction policy	No	Yes	Yes	Yes	Yes
Hazardous waste	—	—	0	0	0
Total waste	—	—	0	0	0
Waste recycled	—	—	—	0	0
Waste sent to landfills	—	—	0	0	0
Environmental supply chain management	No	No	No	No	No
Water policy	No	Yes	Yes	Yes	Yes
Water consumption	—	60	34	37	18
Social					
Human rights policy	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	Yes	Yes
Pct women in workforce	—	—	—	73	83
Pct disabled in workforce	—	—	—	0	—
Business ethics policy	No	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	0	0	0
Total recordable incident rate - employees	—	1	0	0	0
Training policy	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No
Number of employees – CSR	2,083	1,987	2,011	2,208	2,117
Employee turnover pct	—	11	13	10	10
Total hours spent by firm - employee training	14,566	13,462	66,852	81,849	73,676
Social supply chain management	No	No	No	Yes	Yes
Governance					
Board size	10	10	9	9	10
No. of independent directors (ID)	4	7	3	3	7
No. of women on board	2	2	2	2	2
No. of non-executive directors on board	7	7	6	6	7
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	7	7	7	6	6
Board meeting attendance pct	97	100	97	96	98
Board duration (years)	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No
Age of the youngest director	56	56	57	58	51
Age of the oldest director	72	73	74	75	75
No. of executives / company managers	7	5	5	5	6
No. of female executives	2	0	0	0	0
Executive share ownership guidelines	No	No	No	No	No
Size of audit committee	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3
Audit committee meetings	4	4	4	4	4
Audit meeting attendance %	100	100	100	92	100
Size of compensation committee	3	3	3	3	3
No. of ID on compensation committee	3	2	3	3	3
No. of compensation committee meetings	2	2	2	2	2
Compensation meeting attendance %	83	100	100	100	100
Size of nomination committee	3	3	3	3	3
No. of nomination committee meetings	2	2	2	2	2
Nomination meeting attendance %	83	100	100	100	100
Sustainability governance					
Verification type	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology	Rating																			
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																			
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for SETESG inclusion , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETESG Index is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																			
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																			
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																			
Morningstar Sustainalytics	The Sustainalytics' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality & peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table border="1" data-bbox="877 1137 1500 1198"> <thead> <tr> <th>NEGL</th> <th>Low</th> <th>Medium</th> <th>High</th> <th>Severe</th> </tr> </thead> <tbody> <tr> <td>0-10</td> <td>10-20</td> <td>20-30</td> <td>30-40</td> <td>40+</td> </tr> </tbody> </table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+									
NEGL	Low	Medium	High	Severe																	
0-10	10-20	20-30	30-40	40+																	
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																			
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table border="1" data-bbox="239 1388 1500 1601"> <tbody> <tr> <td>AAA</td> <td>8.571-10.000</td> <td rowspan="3">Leader:</td> <td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td> </tr> <tr> <td>AA</td> <td>7.143-8.570</td> </tr> <tr> <td>A</td> <td>5.714-7.142</td> </tr> <tr> <td>BBB</td> <td>4.286-5.713</td> <td rowspan="3">Average:</td> <td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td> </tr> <tr> <td>BB</td> <td>2.857-4.285</td> </tr> <tr> <td>B</td> <td>1.429-2.856</td> </tr> <tr> <td>CCC</td> <td>0.000-1.428</td> <td>Laggard:</td> <td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td> </tr> </tbody> </table>	AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities	AA	7.143-8.570	A	5.714-7.142	BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	BB	2.857-4.285	B	1.429-2.856	CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks
AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities																		
AA	7.143-8.570																				
A	5.714-7.142																				
BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																		
BB	2.857-4.285																				
B	1.429-2.856																				
CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks																		
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																				
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)</i>																				
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																				
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																			
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																			

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) "**SETESG**". The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd

Finansia Syrus Securities Public Company Limited and FSS International Investment Advisory Securities Company Limited are subsidiaries of Finansia X Public Company Limited, with shared directors or executives.


The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Praram 9 Hospital (PR9 TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
11-Apr-2023	BUY	22.00	24-Sep-2024	BUY	27.00	-	-	-
10-Apr-2024	BUY	24.00	02-Dec-2024	BUY	30.00	-	-	-

Vatcharut Vacharawongsith started covering this stock from 4-Sep-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 20.50	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 20-Feb-2026 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.